Oral Antidiabetic Drugs Market Report 2026

The oral antidiabetic drugs market size has grown strongly in recent years. It will grow from $66.73 billion in 2025 to $71.42 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to limited availability of oral antidiabetic drug classes, reliance on conventional biguanides and sulfonylureas, increasing incidence of type 2 diabetes, growing hospital and pharmacy distribution networks, rising awareness of diabetes management.

The oral antidiabetic drugs market size is expected to see strong growth in the next few years. It will grow to $92.64 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to development of novel dpp-4 inhibitors and sglt2 inhibitors, expansion of combination therapies, increasing adoption of personalized medicine approaches, growth of online pharmacy and telemedicine channels, rising government initiatives for diabetes care. Major trends in the forecast period include rising prevalence of type 2 diabetes, increasing adoption of combination oral antidiabetic drugs, expansion of online and retail pharmacy channels, growing focus on personalized diabetes management, enhanced awareness and education on diabetes care.

The rising prevalence of type 2 diabetes is expected to drive growth in the oral antidiabetic drugs market in the coming years. Type 2 diabetes is a chronic condition in which the body either resists insulin or does not produce enough to maintain normal blood glucose levels. Its increasing prevalence is largely linked to rising obesity rates, as excess body fat contributes to insulin resistance and impaired glucose regulation. Oral antidiabetic drugs help manage type 2 diabetes by enhancing insulin sensitivity, stimulating insulin secretion, or reducing glucose production and absorption, thereby maintaining healthy blood sugar levels. For example, in March 2025, the Office for Health Improvement and Disparities, a UK-based government agency, reported that type 2 diabetes prevalence among adults aged 17 and older in England rose to 7%, up from 6.8% in March 2023. This demonstrates that the rising prevalence of type 2 diabetes is fueling the oral antidiabetic drugs market.

Key companies in the oral antidiabetic drugs market are focusing on clinical trials to develop safer and more effective therapies, expand their product offerings, and secure regulatory approvals for next-generation treatments. Clinical trials are controlled studies conducted on human participants to evaluate the safety, efficacy, and side effects of new treatments. For instance, in April 2025, Eli Lilly and Company, a U.S.-based pharmaceutical firm, introduced Orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist, following successful phase 3 trials. This oral therapy is designed to deliver efficacy and safety comparable to injectable options while improving patient adherence. In trials, Orforglipron lowered HbA1c - a key blood sugar marker - by 1.3% to 1.6% across different doses over 40 weeks.

In January 2024, Roche Group, a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics Inc. for an undisclosed sum. Through this acquisition, Roche aimed to enhance its pipeline in diabetes and obesity treatments by leveraging Carmot’s innovative small-molecule therapies targeting incretin biology. Carmot Therapeutics, a U.S.-based firm, develops oral antidiabetic drugs, including CT-996, a once-daily oral small-molecule GLP-1 receptor agonist.

Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited.

North America was the largest region in the oral antidiabetic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral antidiabetic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the oral antidiabetic drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and finished products, leading to higher prices for key drug classes like SGLT2 inhibitors and DPP-4 inhibitors. Hospital pharmacies and retail pharmacies in regions such as North America and Asia-Pacific, including India and China, are particularly impacted. While tariffs pose challenges in supply chain and cost management, they also encourage local manufacturing and the development of domestically produced drug formulations, supporting long-term market resilience.

The oral antidiabetic drugs market research report is one of a series of new reports that provides oral antidiabetic drugs market statistics, including oral antidiabetic drugs industry global market size, regional shares, competitors with a oral antidiabetic drugs market share, detailed oral antidiabetic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the oral antidiabetic drugs industry. This oral antidiabetic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral antidiabetic drugs are medications taken by mouth to help manage and control blood glucose levels in individuals with type 2 diabetes. These drugs act through various mechanisms, including increasing insulin sensitivity, stimulating insulin secretion, or reducing glucose production in the liver. They play a vital role in diabetes management to prevent complications and support long-term health.

The main drug classes of oral antidiabetic medications include biguanides, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, sulfonylureas, thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, and others. Biguanides, for example, primarily lower blood glucose by reducing hepatic glucose production and enhancing insulin sensitivity. These drugs are administered via oral, sublingual, or buccal routes and are used in therapeutic areas such as type 2 diabetes, gestational diabetes, and type 1 diabetes. They are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and serve key end users including hospitals, pharmacy stores, drugstores, diabetes treatment centers, and more.

The oral antidiabetic drugs market consists of sales of dual or combination oral therapies, glucokinase activators, and amylin analogs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.